Eliem Therapeutics (ELYM)
(Delayed Data from NSDQ)
$8.88 USD
+0.40 (4.72%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $8.84 -0.04 (-0.45%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Eliem Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 40 | 45 | 36 | 21 | 0 |
Income After Depreciation & Amortization | -40 | -45 | -36 | -21 | 0 |
Non-Operating Income | 5 | 0 | -12 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -35 | -45 | -47 | -21 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -35 | -45 | -47 | -21 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -35 | -45 | -47 | -21 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -45 | -35 | -21 | 0 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -40 | -45 | -36 | -21 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 26.31 | 12.26 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | -1.72 | -4.24 | NA | NA |
Diluted Net EPS (GAAP) | -1.30 | -1.72 | -4.24 | NA | NA |
Fiscal Year end for Eliem Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 3.00 | 5.13 | 5.01 | 6.72 | 23.44 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.00 | -5.13 | -5.01 | -6.72 | -23.44 |
Non-Operating Income | 1.31 | 1.48 | 1.03 | 1.49 | 1.15 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -1.70 | -3.64 | -3.97 | -5.22 | -22.29 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -1.70 | -3.64 | -3.97 | -5.22 | -22.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -1.70 | -3.64 | -3.97 | -5.22 | -22.29 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 27.64 | NA | 27.00 | 26.84 | 26.54 |
Diluted EPS Before Non-Recurring Items | -0.06 | NA | -0.15 | -0.19 | -0.84 |
Diluted Net EPS (GAAP) | -0.06 | -0.12 | -0.15 | -0.19 | -0.84 |